Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

被引：0

作者：

Akio Nakasya

Yuya Hagiwara

Tatsuki Ikoma

Yusuke Kurioka

Toshihiko Matsumoto

Yoshiyuki Yamamoto

Takao Tsuduki

Takeshi Kajiwara

Toshikazu Moriwaki

Tomohiro Nishina

Natsumi Yamashita

Ichinosuke Hyodo

机构：

[1] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology

[2] University of Tsukuba,Department of Gastroenterology, Faculty of Medicine

[3] Kobe City Medical Center General Hospital,Department of Medical Oncology

[4] Himeji Red Cross Hospital,Department of Internal Medicine

[5] National Hospital Organization Shikoku Cancer Center,Section of Cancer Prevention and Epidemiology, Clinical Research Center

来源：

International Journal of Clinical Oncology | 2022年 / 27卷

关键词：

Gastric cancer; Chemotherapy; Albumin-bound paclitaxel; Paclitaxel; Ramucirumab; Propensity score;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：684 / 694

页数：10

共 50 条

[41] Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
Hirano, Hidekazu
Takahashi, Naoki
Amanuma, Yusuke
Suzuki, Nobumi
Takahari, Daisuke
Kawakami, Takeshi
Kudo-Saito, Chie
Nagashima, Kengo
Boku, Narikazu
Kato, Ken
Shoji, Hirokazu
BMC CANCER, 2025, 25 (01)
[42] A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
Yusuke Okuma
Yukio Hosomi
Satoshi Takahashi
Yoshiro Nakahara
Kageaki Watanabe
Makoto Nagamata
Yusuke Takagi
Shinichiro Mikura
Cancer Chemotherapy and Pharmacology, 2016, 78 : 383 - 388
[43] A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer
Okuma, Yusuke
Hosomi, Yukio
Takahashi, Satoshi
Nakahara, Yoshiro
Watanabe, Kageaki
Nagamata, Makoto
Takagi, Yusuke
Mikura, Shinichiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 383 - 388
[44] Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
Zheng, Yulong
Fang, Weijia
Mao, Chenyu
Qian, Joing
Zhao, Peng
Zhang, Xiaochen
Jiang, Haiping
Zheng, Yi
Xu, Nong
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 503 - 509
[45] Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
Yulong Zheng
Weijia Fang
Chenyu Mao
Joing Qian
Peng Zhao
Xiaochen Zhang
Haiping Jiang
Yi Zheng
Nong Xu
Cancer Chemotherapy and Pharmacology, 2014, 74 : 503 - 509
[46] Weekly albumin-bound paclitaxel/cisplatin versus gemcitabine/cisplatin as first-line therapy for patients with advanced non-small-cell lung cancer: A phase II open-label clinical study
Qin, Shanshan
Yu, Hui
Wu, Xianghua
Luo, Zhiguo
Wang, Huijie
Sun, Si
Huang, Mingzhu
Jin, Jia
Tao, Zhonghua
Qiao, Jie
Feng, Yu
Wang, Jialei
Chang, Jianhua
CHINESE JOURNAL OF CANCER RESEARCH, 2019, 31 (02) : 339 - 348
[47] First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study
Akitaka Makiyama
Kenji Kunieda
Masaaki Noguchi
Takeshi Kajiwara
Takao Tamura
Koji Takeda
Junko Sugiyama
Keiko Minashi
Toshikazu Moriwaki
Naotoshi Sugimoto
Michitaka Nagase
Yuji Negoro
Takashi Tsuda
Hideki Shimodaira
Naohiro Okano
Akihito Tsuji
Daisuke Sakai
Kazuhiro Yanagihara
Shinya Ueda
Shingo Tamura
Satoshi Otsu
Takuya Honda
Yuzo Matsushita
Tatsuya Okuno
Tomomi Kashiwada
Akira Nozaki
Masahide Ebi
Hiroyuki Okuda
Mototsugu Shimokawa
Shuichi Hironaka
Ichinosuke Hyodo
Eishi Baba
Narikazu Boku
Kei Muro
Taito Esaki
Gastric Cancer, 2018, 21 : 792 - 801
[48] First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study
Makiyama, Akitaka
Kunieda, Kenji
Noguchi, Masaaki
Kajiwara, Takeshi
Tamura, Takao
Takeda, Koji
Sugiyama, Junko
Minashi, Keiko
Moriwaki, Toshikazu
Sugimoto, Naotoshi
Nagase, Michitaka
Negoro, Yuji
Tsuda, Takashi
Shimodaira, Hideki
Okano, Naohiro
Tsuji, Akihito
Sakai, Daisuke
Yanagihara, Kazuhiro
Ueda, Shinya
Tamura, Shingo
Otsu, Satoshi
Honda, Takuya
Matsushita, Yuzo
Okuno, Tatsuya
Kashiwada, Tomomi
Nozaki, Akira
Ebi, Masahide
Okuda, Hiroyuki
Shimokawa, Mototsugu
Hironaka, Shuichi
Hyodo, Ichinosuke
Baba, Eishi
Boku, Narikazu
Muro, Kei
Esaki, Taito
GASTRIC CANCER, 2018, 21 (05) : 792 - 801
[49] Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non-Small-Cell Lung Cancer Pretreated With Non-Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study
Pallis, Athanasios G.
Syrigos, Kostas
Kotsakis, Athanasios
Karachaliou, Niki
Polyzos, Aris
Chandrinos, Vassilis
Varthalitis, Ioannis
Christophyllakis, Charalambos
Ardavanis, Alexandros
Vamvakas, Lambros
Vardakis, Nikolaos
Saridaki, Zacharenia
Samonis, George
Giassas, Stylianos
Georgoulias, Vassilis
Agelaki, Sophia
CLINICAL LUNG CANCER, 2011, 12 (02) : 100 - 105
[50] ASO Visual Abstract: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score-A Multicenter Study
Nakazawa, Nobuhiro
Sohda, Makoto
Hosoi, Nobuhiro
Watanabe, Takayoshi
Kumakura, Yuji
Yamashita, Toshiki
Tanaka, Naritaka
Saito, Kana
Kimura, Akiharu
Kasuga, Kengo
Nakazato, Kenji
Yoshinari, Daisuke
Shimizu, Hisashi
Ubukata, Yasunari
Hosaka, Hisashi
Sano, Akihiko
Sakai, Makoto
Ogawa, Hiroomi
Shirabe, Ken
Saeki, Hiroshi
ANNALS OF SURGICAL ONCOLOGY, 2024, : 9065 - 9066

← 1 2 3 4 5 →